Applied DNA Sciences (APDN) Terminates Equity Distribution Agreement

On November 7, 2023, Applied DNA Sciences (NASDAQ: APDN) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Maxim Group LLC, as sales agent (the “Agent”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, in an aggregate offering price of up to $6,397,939 through the Agent. Under the terms of the Equity Distribution Agreement, the Agent may sell the shares of common stock at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended. 90,027 shares of common stock were sold pursuant to the Equity Distribution Agreement. Effective January 30, 2024, the Company terminated the Equity Distribution Agreement by providing a notice of termination to the Agent in accordance with the terms of the Equity Distribution Agreement.

You May Also Be Interested In

• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• Lightwave Logic, Inc. (LWLG) files mixed shelf
• Broadstone Net Lease adds $40M Tesla facility to development pipeline